{"id":"W2604901999","doi":"10.1080/21556660.2017.1315336","title":"Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma","year":2017,"lang":"en","type":"article","venue":"Journal of Drug Assessment","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"CD22; Medicine; Refractory (planetary science); Calicheamicin; Lymphoma; Internal medicine; Oncology; CD20","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001023971,0.001148154,0.00181583,0.0003097122,0.0003199836,0.0007075715,0.0007335089,0.0006866509,0.001629749],"category_scores_gemma":[0.0006153464,0.0004762282,0.0006963826,0.0002719772,0.0006741449,0.0005685523,0.0002874408,0.002058132,0.0004626241],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007646114,"about_ca_system_score_gemma":0.001175639,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007619043,"about_ca_topic_score_gemma":0.002290367,"domain_scores_codex":[0.9996781,0.0001637109,0.00001449072,0.0000564671,0.00003372917,0.00005338993],"domain_scores_gemma":[0.9996477,0.00005082905,0.00008469437,0.00003079141,0.00002373038,0.0001622406],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4914964,0.1151799,0.01602267,0.001550826,0.002575628,0.00092591,0.0008292813,0.005477171,0.1693881,0.0003882249,0.004239894,0.1919261],"study_design_scores_gemma":[0.3567466,0.6057998,0.01949683,0.00004704341,0.0007163105,0.0005912547,0.00007493666,0.00172333,0.01133778,0.0001026901,0.003332459,0.00003101082],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965118,0.001162061,0.0003253003,0.0001597419,0.00004052767,0.0009300906,0.0002292404,0.00004513795,0.0005962704],"genre_scores_gemma":[0.9953916,0.001084941,0.000921005,0.0002871216,0.00007868038,0.0008251739,0.000646651,0.00001549657,0.0007493457],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00181583,"threshold_uncertainty_score":0.005547643,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01537253524744568,"score_gpt":0.3181207012641905,"score_spread":0.3027481660167448,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}